Broader macroeconomic uncertainty has resulted in continued caution for both investors and acquirers in the in vitro diagnostics sector.

Of the 30 companies included in the list, 24 firms saw their stock prices rise, four saw their share prices decline, and two saw their stock prices remain flat.